Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4.

MLA

Stam, Marloes, et al. “Randomized Double-Blind Placebo-Controlled Crossover Trial with Pyridostigmine in Spinal Muscular Atrophy Types 2-4.” Brain Communications, vol. 5, no. 1, Dec. 2022, p. fcac324. EBSCOhost, https://doi.org/10.1093/braincomms/fcac324.

APA

Stam, M., Wijngaarde, C. A., Bartels, B., Asselman, F.-L., Otto, L. A. M., Habets, L. E., van Eijk, R. P. A., Middelkoop, B. M., Goedee, H. S., de Groot, J. F., Roes, K. C. B., Schoenmakers, M. A. G. C., Nieuwenhuis, E. E. S., Cuppen, I., van den Berg, L. H., Wadman, R. I., & van der Pol, W. L. (2022). Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4. Brain Communications, 5(1), fcac324. https://doi.org/10.1093/braincomms/fcac324

Chicago

Stam, Marloes, Camiel A Wijngaarde, Bart Bartels, Fay-Lynn Asselman, Louise A M Otto, Laura E Habets, Ruben P A van Eijk, et al. 2022. “Randomized Double-Blind Placebo-Controlled Crossover Trial with Pyridostigmine in Spinal Muscular Atrophy Types 2-4.” Brain Communications 5 (1): fcac324. doi:10.1093/braincomms/fcac324.